Priya Vijayvargiya1, Michael Camilleri2. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton Bldg., Rm. 8-110, 200 First Street S.W, Rochester, MN, 55905, USA. 2. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton Bldg., Rm. 8-110, 200 First Street S.W, Rochester, MN, 55905, USA. camilleri.michael@mayo.edu.
Abstract
PURPOSE OF REVIEW: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). RECENT FINDINGS: •Molecular mechanisms-BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease-new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis-BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing-new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment-investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.
PURPOSE OF REVIEW: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). RECENT FINDINGS: •Molecular mechanisms-BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease-new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis-BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing-new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment-investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.
Authors: F Fernández-Bañares; M Rosinach; M Piqueras; A Ruiz-Cerulla; I Modolell; Y Zabana; J Guardiola; M Esteve Journal: Aliment Pharmacol Ther Date: 2015-04-10 Impact factor: 8.171
Authors: Joseph B J Ward; Natalia K Lajczak; Orlaith B Kelly; Aoife M O'Dwyer; Ashwini K Giddam; Joan Ní Gabhann; Placido Franco; Murtaza M Tambuwala; Caroline A Jefferies; Simon Keely; Aldo Roda; Stephen J Keely Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-03-30 Impact factor: 4.052
Authors: M Camilleri; A Acosta; I Busciglio; A Boldingh; R B Dyer; A R Zinsmeister; A Lueke; A Gray; L J Donato Journal: Aliment Pharmacol Ther Date: 2015-01-16 Impact factor: 8.171
Authors: Ivan Lyutakov; Francesco Ursini; Plamen Penchev; Giacomo Caio; Antonio Carroccio; Umberto Volta; Roberto De Giorgio Journal: BMC Gastroenterol Date: 2019-11-14 Impact factor: 3.067
Authors: Virginia Flores; Helena Martínez-Lozano; Federico Bighelli; Javier Orcajo; Javier García-Lledó; Juan Carlos Alonso-Farto; Luis Menchén Journal: BMC Gastroenterol Date: 2021-02-09 Impact factor: 3.067
Authors: H R Wardill; C E M de Mooij; A R da Silva Ferreira; I P van de Peppel; R Havinga; H J M Harmsen; W J E Tissing; N M A Blijlevens Journal: Cancer Chemother Pharmacol Date: 2021-04-20 Impact factor: 3.333